Modulatory effects of modafinil on neural circuits regulating emotion and cognition

Neuropsychopharmacology

Volumn 35, Issue 10, 2010, Pages 2101-2109

  Rasetti, Roberta ^a   Mattay, Venkata S ^a   Stankevich, Beth ^a   Skjei, Kelsey ^a   Blasi, Giuseppe ^a,b   Sambataro, Fabio ^a,c   Arrillaga Romany, Isabel C ^a   Goldberg, Terry E ^a,d   Callicott, Joseph H ^a   Apud, José A ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF BARI   (Italy)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

amygdala; cognitive processing; emotion; fMRI; healthy volunteers; Modafinil

Indexed keywords

MODAFINIL; PLACEBO;

ADULT; AMYGDALOID NUCLEUS; ANGER; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EMOTION; FATIGUE; FEAR; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HAMILTON ANXIETY SCALE; HEART RATE; HOSTILITY; HUMAN; HUMAN EXPERIMENT; INFORMATION PROCESSING; LOW DRUG DOSE; MALE; NERVE CELL NETWORK; NEUROIMAGING; NORMAL HUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROFILE OF MOOD STATES; RANDOMIZED CONTROLLED TRIAL; TASK PERFORMANCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WORKING MEMORY;

ADULT; BENZHYDRYL COMPOUNDS; BRAIN; BRAIN MAPPING; COGNITION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EMOTIONS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; OXYGEN; STATISTICS AS TOPIC;

EID: 77955715528     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.83     Document Type: Article

References (52)

1. Angrist BM, Gershon S (1970). The phenomenology of experimentally induced amphetamine psychosisFpreliminary observations. Biol Psychiatry 2: 95-107
2. APA (1994). DSM-IV. Diagnostic and statistical manual. 4th edn, American Psychiatry Association: Washington, DC.
3. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R et al (2007). Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsy-chopharmacology 32: 1011-1020.
4. Becker PM, Schwartz JR, Feldman NT, Hughes RJ (2004). Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. Psychopharmacology (Berl) 171: 133-139.
5. Blasi G, Mattay VS, Bertolino A, Elveva?g B, Callicott JH, Das S et al (2005). Effect of catechol-o-methyltransferase val158met genotype on attentional control. J Neurosci 25: 5038-5045.
6. Brennan AR, Arnsten AF (2008). Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann NY Acad Sci 1129: 236-245.
7. Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H et al (1997). Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 49: 444-451.
8. Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinksi B et al (2003). Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 160: 709-719.
9. Cools R, Robbins TW (2004). Chemistry of the adaptive mind. Philos Transact A Math Phys Eng Sci 362: 2871-2888.
10. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM (2002). Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 125: 584-594.
11. Deroche-Gamonet V, Darnaudéry M, Bruins-Slot L, Piat F, Le Moal M, Piazza PV (2002). Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology (Berl) 161: 387-395.
12. Ekman P, Friesen WV (1976). Pictures of Facial Affect. Consulting Psychologist Press: Palo Alto, CA.
13. Ellinwood Jr EH, Sudilovsky A, Nelson LM (1973). Evolving behavior in the clinical and experimental amphetamine (model) psychosis. Am J Psychiatry 130: 1088-1093.
14. Friston KJ, Zarahn E, Josephs O, Henson RN, Dale AM (1999). Stochastic designs in event-related fMRI. Neuroimage 10: 607-619.
15. Gibbs SE, D'Esposito M (2005). A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory. Psychopharmacology (Berl) 180: 644-653.
16. Gibbs SE, D'Esposito M (2006). A functional magnetic resonance imaging study of the effects of pergolide, a dopamine receptor agonist, on component processes of working memory. Neuroscience 139: 359-371.
17. Gorman SH (2002). Determination of modafinil, modafinil acid and modafinil sulfone in human plasma utilizing liquid-liquid extraction and high-performance liquid chromato-graphy. J Chromatogr B Analyt Technol Biomed Life Sci 767: 269-276.
18. Hall RC, Popkin MK, Beresford TP, Hall AK (1988). Amphetamine psychosis: clinical presentations and differential diagnosis. Psychiatr Med 6: 73-79.
19. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
20. Hariri AR, Mattay VS, Tessitore A, Fera F, Smith WG, Weinberger DR (2002). Dextroamphetamine modulates the response of the human amygdala. Neuropsychopharmacology 27: 1036-1040.
21. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM (2006). Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 59: 816-820.
22. Hermant JF, Rambert FA, Duteil J (1991). Awakening properties of modafinil: effect on nocturnal activity in monkeys (Macaca mulatta) after acute and repeated administration. Psychopharmacology (Berl) 103: 28-32.
23. Hunter MD, Ganesan V, Wilkinson ID, Spence SA (2006). Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry 163: 2184-2186.
24. Jr JL, Regan C, Stump G, Tannenbaum P, Stevens J, Bone A et al (2009). Hemodynamic and cardiac neurotransmitter-releasing effects in conscious dogs of attention-and wake-promoting agents: a comparison of d-amphetamine, atomoxetine, modafi-nil, and a novel quinazolinone H3 inverse agonist. J Cardiovasc Pharmacol 53: 52-59.
25. MacDonald JR, Hill JD, Tarnopolsky MA (2002). Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 59: 1876-1880.
26. Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L et al (2006). Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319: 561-569.
27. Makris AP, Rush CR, Frederich RC, Kelly TH (2004). Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 42: 185-195.
28. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF et al (2003). Catechol o-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 100: 6186-6191.
29. Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN et al (2002). Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 51: 156-164.
30. McNair DM, Lorr M, Droppleman LF (1992). Revised Manual for the Profile of Mood States. Educational and Industrial Testing Service: San Diego, CA.
31. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW (2000). Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci 20: RC65.
32. Minzenberg MJ, Carter CS (2008). Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33: 1477-1502.
33. Minzenberg MJ, Watrous AJ, Yoon JH, Ursu S, Carter CS (2008). Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI. Science 322: 1700-1702.
34. Norbury R, Mackay CE, Cowen PJ, Goodwin GM, Harmer CJ (2007). Short-term antidepressant treatment and facial processing. Functional magnetic resonance imaging study. Br J Psychiatry 190: 531-532.
35. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS et al (2005). 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 8: 828-834
36. Provigil website. http://www.provigil.com/media/PDFs/prescribing- info.pdf Accessed 29 March 29 2010 2010.
37. Qu WM, Huang ZL, Xu XH, Matsumoto N, Urade Y (2008). Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci 28: 8462-8469.
38. Robertson Jr P, Hellriegel ET (2003). Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 42: 123-137.
39. Saletu M, Anderer P, Semlitsch HV, Saletu-Zyhlarz GM, Mandl M, Zeitlhofer J et al (2007). Low-resolution brain electromagnetic tomography (LORETA) identifies brain regions linked to psychometric performance under modafinil in narcolepsy. Psychiatry Res 154: 69-84.
40. Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM (2006). Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers. J Psychopharmacol 20: 756-770.
41. Schwartz JR, Hirshkowitz M, Erman MK, Schmidt-Nowara W (2003). Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 124: 2192-2199.
42. Simon P, Panissaud C, Costentin J (1994). The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice. A comparison with dexamphetamine. Psycho-pharmacology (Berl) 114: 597-600.
43. Spence SA, Green RD, Wilkinson ID, Hunter MD (2005). Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry 187: 55-61.
44. Tan HY, Callicott JH, Weinberger DR (2007). Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 17(Suppl 1): i171-i181.
45. Taneja I, Haman K, Shelton RC, Robertson D (2007). A randomized, double-blind, crossover trial of modafinil on mood. J Clin Psychopharmacol 27: 76-79.
46. Thomas RJ, Kwong K (2006). Modafinil activates cortical and subcortical sites in the sleep-deprived state. Sleep 29: 1471-1481.
47. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 165: 260-269.
48. van Vliet SA, Jongsma MJ, Vanwersch RA, Olivier B, Philippens IH (2006). Behavioral effects of modafinil in marmoset monkeys. Psychopharmacology (Berl) 185: 433-440.
49. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F et al (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301: 1148-1154.
50. Wesensten NJ (2006). Effects of modafinil on cognitive performance and alertness during sleep deprivation. Curr Pharm Des 12: 2457-2471.
51. Winder-Rhodes S, Chamberlain S, Idris M, Robbins T, Sahakian B, Müller U (2010). Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers. J Psychopharmacol, print copy in press (originally published online 3 Jun 2009, at http://jop.sagepub.com/cgi/ rapidpdf/0269881109105899v1).
52. Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM (2002). Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 249: 983-987.